OraSure Plans To File Over-The-Counter HIV Test Application By Year End
This article was originally published in The Tan Sheet
Executive Summary
OraSure Technologies says it expects this year to complete a pre-market application for its OraQuick Advance Rapid HIV-1 and -2 over-the-counter saliva test. The product would be the first HIV diagnostic intended for use at home and providing results directly to the user.
You may also be interested in...
Advisory Panel Endorses OraSure In-Home HIV Test
An FDA advisory committee endorses OraSure’s OraQuick in-home HIV test in a unanimous vote. If approved, OraQuick would be the first OTC test for HIV that untrained users can perform entirely in the home.
Advisory Panel Endorses OraSure In-Home HIV Test
An FDA advisory committee endorses OraSure’s OraQuick in-home HIV test in a unanimous vote. If approved, OraQuick would be the first OTC test for HIV that untrained users can perform entirely in the home.
The Future Of OTCs: Self-Selection Meets Diagnostics, Genetic Personalization
The next generation of consumer health products, including Rx-to-OTC switch opportunities, may work in concert with cutting-edge diagnostic tools and elements of personalized medicine, says Andrew Fish.